CELU Celularity Inc: רווח למניה בשנים עשר החודשים האחרונים

Liquidity shortages resulting from costly cell development are weighing on Celularity Inc. (CELU) shares, and the net income per share over the last 12 months shows a downward trend, with the current level sitting around -1.67. Meanwhile, management aims to monetize aesthetic technologies, while a strong scientific team expands the patent portfolio supported by generous R&D budgets.

Earnings per share (EPS TTM) measures the actual portion of profit attributable to a single security over a trailing twelve-month period. For Celularity Inc. (CELU), this metric reflects the monetization efficiency of allogeneic platforms and the costs associated with maintaining the biobank. By analyzing the trailing twelve-month earnings per share snapshot, an investor can separate market noise from fundamental growth. The trend of this indicator demonstrates the company's ability to convert clinical trials into capital. A stable trend in this metric confirms the resilience of the business model against speculative risks.